Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Iovance Biotherapeutics’ (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman

In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company’s shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply contradicted earlier upbeat assurances from management.

Hagens Berman is now investigating whether Iovance violated U.S. securities laws and urges Iovance investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Visit: www.hbsslaw.com/investor-fraud/iova

Contact the Firm Now: IOVA@hbsslaw.com

844-916-0895

Iovance, which develops and commercializes novel cell therapies-most notably Amtagvi, its tumor-infiltrating lymphocyte (TIL) therapy for melanoma and metastatic cervical cancer-has positioned itself as a leader in harnessing the immune system to target cancer cells.

Confident Statements on Maintenance

Earlier this year, Iovance’s management painted a reassuring picture for investors regarding its annual maintenance cycle. On February 27, executives emphasized that each facility’s maintenance required only a “short pause in production,” and declared, “I’m pleased to report that iCTC successfully completed annual maintenance and resumed production promptly at full volume with no issues.” The company’s state-of-the-art Iovance Cell Therapy Center (iCTC) in Philadelphia, a 136,000-square-foot manufacturing hub, was said to be back online without disruption.

Reality Unveiled

That narrative shifted abruptly with Iovance’s Q1 2025 earnings report. The company reported a loss of 36 cents a share on revenue of $49 million, well short of Wall Street’s consensus for a loss of 24 cents on revenue of $82 million. On the subsequent earnings call, Chief Operating Officer Igor Bilinsky disclosed that the iCTC’s annual maintenance had actually reduced capacity by 50% for an entire month in December 2024-an operational bottleneck that limited the number of Amtagvi infusions available in the first quarter.

This news sent the price of Iovance shares down $1.42, or about 44% lower, on May 9, 2025.

Hagens Berman’s Investigation

In the wake of these revelations, Hagens Berman, a prominent class action law firm, announced it has opened an investigation into potential violations of U.S. securities laws by Iovance. The investigation focuses on the propriety of Iovance’s disclosures concerning the adverse financial impact associated with its annual maintenance of its iCTC.

“We’re concerned that Iovance may have misled investors about the magnitude of the adverse financial impact resulting from iCTC maintenance,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Iovance and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the Iovance investigation, read more »

Whistleblowers: Persons with non-public information regarding Iovance should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email IOVA@hbsslaw.com.

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contacts

Reed Kathrein, 844-916-0895

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.